OBJECTIVES: To analyze the chronic obstructive pulmonary disease (COPD) treatments submitted to the Brazilian National Committee for Health Technology Incorporation (CONITEC) by comparing the main points of CONITEC analysis in order to classify each one as a strong or weak point for each treatment.

METHODS: An analysis on the appraisal reports of COPD treatments available in the CONITEC database between 2012 and 2022 have been undertaken on the following criteria: efficacy; adverse events; administration route; economic evaluation; comparators and budget impact analysis. To accomplish this, a multi-criteria decision analysis (MCDA) approach has been applied to classify each criterion as a strong or weak point for each treatment through an outranking relation.

RESULTS: The following timeline of submitted COPD treatments to CONITEC have been formed: roflumilast (Oct. 2012, negative appraisal); indacaterol (Mar. 2013, negative appraisal); fluticasone (Aug. 2013, negative appraisal); tiotropium (Aug. 2013, negative appraisal); LAMA-LABA (Dec. 2020, positive appraisal). For roflumilast adverse events and efficacy have been identified as strong points. All criteria have been identified as strong points for indacaterol. Administration route; adverse events; and comparators were the strong points for fluticasone. Comparators and economic evaluation were the weak points for tiotropium. Comparators and adverse events have been identified as weak points for LAMA-LABA.

CONCLUSIONS: This work analyzed the appraisal reports of COPD treatments from the CONITEC database generating a classification for the criteria of analysis as evidence using an MCDA approach. Indacaterol has achieved all criteria as strong points and negative appraisal by CONITEC. On the other hand, two weak points have been identified for LAMA-LABA, that has received positive appraisal.